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INTRODUCTION 
Prolactinoma is the most common functioning pituitary
adenoma with excellent medical response. Invasive giant
prolactinoma, an extreme subset of prolactinoma, is charac-
terized by large size (>40 mm in diameter), high aggressive-
ness, massive extrasellar involvement and very high plasma
prolactin levels, usually >1,000 ng/mL (1, 2). Although micro-
prolactinoma is found predominantly in young female pati-
ents, invasive giant prolactinoma is prevalent in young male
patients (3). Patients with giant prolactinoma usually present
with symptoms or signs caused by the compression of sur-
rounding structures by large or invasive tumors, including
headache, visual disturbance, and/or diplopia. Many patients
also have symptoms or signs of hypopituitarism, including
hypogonadism. 
Dopamine agonists are used in the first line treatment for
prolactinoma. Surgery is indicated for patients non-respon-
sive or intolerant to dopamine agonists, as well as in patients
with invasive macroadenomas and compromised vision who
do not rapidly improve after medical treatment. Although
the dopamine agonist bromocriptine has been widely used
in patients with prolactinoma, the more recently developed
dopamine agonist cabergoline is longer-acting and more selec-
tive for the dopamine type 2 (D2)-receptor. Moreover, caber-
goline has been found to be more effective and better toler-
ated than bromocriptine in normalizing prolactin levels and
shrinking tumors in both men and women (4). Here we re-
port 10 cases of invasive giant prolactinoma, which were suc-
cessfully treated with cabergoline alone.
MATERIALS AND METHODS
Patients
The present study included all patients, who were diag-
nosed with invasive giant prolactinoma at the pituitary clin-
ic of Asan Medical Center between April 2003 and June 2007
and treated only with cabergoline. All met the criteria for
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Efficacy and Safety of Cabergoline as First Line Treatment for 
Invasive Giant Prolactinoma
Although cabergoline is effective in the treatment of micro- and macro-prolactinoma,
little is known about its efficacy in the treatment of invasive giant prolactinoma. We
investigated the efficacy and safety of cabergoline in 10 male patients with invasive
giant prolactinoma. Before treatment, mean serum prolactin level was 11,426 ng/mL
(range, 1,450-33,200 ng/mL) and mean maximum tumor diameter was 51 mm (ran-
ge, 40-77 mm). Three months after initiation of cabergoline treatment, serum pro-
lactin concentrations decreased more than 97% in 9 patients; at last follow-up (mean
treatment duration, 19 months), the mean decrease in serum prolactin concentra-
tions was 98%, with 5 patients having normal serum prolactin levels. At first MRI
follow-up (3-12 months after initiation of cabergoline), the mean reduction in tumor
size was 85±4% (range, 57-98%). Cabergoline treatment for more than 12 months
caused a greater reduction in tumor size compared to the treatment for less than
12 months (97±1% vs. 78±7%, P<0.05). These findings indicate that cabergo-
line treatment led to a significant and rapid reduction in serum prolactin concentra-
tions and tumor size in patients with giant prolactinoma. Therefore, cabergoline re-
presents an effective and well-tolerated treatment for invasive giant prolactinoma. 
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invasive giant prolactinomas: tumor diameter >40 mm, serum
prolactin concentrations >1,000 ng/mL, and invasive extra-
sellar tumor growth. None of these patients had undergone
surgery or radiotherapy for prolactinoma and none had a his-
tory of treatment with dopamine agonists. This study was
performed retrospectively and approved by the ethical review
board of Asan Medical Center. All individuals agreed to par-
ticipate in the study and gave informed consent.
Treatment protocol
All patients received oral cabergoline at a starting dose of
0.5 mg once weekly. Based on serum prolactin concentrations,
the dose of cabergoline was increased 0.5 mg/week every 3
to 6 months, to a maximum dose of 1.5 mg twice per week
(total 3 mg per week). During treatment, all patients visit-
ed the clinic every 3 months, at which time serum prolactin
concentrations were monitored. All patients were asked to
report any side effects. Other pituitary function tests were
performed before and during treatment, if warranted. Change
in tumor size was monitored using sellar magnetic resonance
imaging (MRI).
Hormone assays
Serum prolactin levels were measured by an immunora-
diometric assay using commercial kits (TFB, Tokyo, Japan).
The lowest detectible level of serum prolactin is 1.0 ng/mL,
and its intra- and inter-assay coefficients of variation for pro-
lactin concentrations were 7.1% and 3.6% respectively. The
reference prolactin levels for men are 1.5-9.7 ng/mL. If serum
prolactin levels were over 300 ng/mL, serum were serially
diluted and subjected to remeasurement. Serum total testos-
terone concentrations were determined by radioimmunoas-
say (Adaltis Italia S.P.A., Italy) and the reference levels for
testosterone are 2.8-8.8 ng/mL. 
Magnetic resonance imaging
Pituitary tumor volume was evaluated using 0.5 or 1.5 T
MRI scanners in the sagittal, coronal, and axial planes before
and after gadolinium administration. Pituitary tumor vol-
ume was calculated from the major transverse, antero-poste-
rior and cranio-caudal diameters. Pituitary tumor shrinkage
was evaluated by the percentage reduction in tumor volume.
Statistical analysis
Results are expressed as mean±S.E.M. Treatment-associat-
ed changes in tumor-related parameters were statistically ana-
lyzed using paired Student’s t-test (version 15; SPSS, Chicago,
IL, U.S.A.). P<0.05 was considered statistically significant.
RESULTS
During the study period, 10 male patients were diagnosed
with invasive giant prolactinoma; at diagnosis, mean age was
37±4 yr (range, 25-59 yr). Of these 10 patients, 4 had visu-
al field defects and headache and 3 had only headache. One
patient (No. 10) had nasal obstruction and bleeding, which
resulted from a tumor growing downward to the infrasellar
area. The remaining two patients had no symptoms; their
tumors were accidentally found during routine checkup of
brain MRI or CT. Seven patients had low serum testosterone
concentrations (<2.8 ng/mL), and one (No. 2) had panhypopi-
tuitarism at diagnosis. Before treatment, mean serum prolactin
concentration was 11,426 ng/mL (range, 1,450-33,200 μ g/mL)
and mean maximal tumor diameter was 51 mm (range, 40-
77 mm). 
Seven patients received 0.5-1 mg cabergoline per week with
no dose increment throughout the treatment period. The dose
of cabergoline was increased to 2 mg per week in 2 patients
(Nos. 7 and 10) and to 3 mg per week in one patient (No. 6).
Case
No.
Age
(yr)
Basal
prolactin
(ng/mL)
Treatment
duration
(months)
Treatment
duration
(months)
Prolactin
(ng/mL)
Decrease 
(% of basal)
Prolactin
(ng/mL)
Decrease
(% of basal)
Initial follow-up Last follow-up
1 29 30,000 3 1,590 95 43 13 99
2 36 4,880 3 25 99 24 21 99
3 32 2,520 3 131 95 9 3.7 99
4 33 9,310 3 433 95 9 154 98
5 28 6,110 3 15 99 9 8.4 99
6 25 33,200 3 244 99 21 181 99
7 50 6,340 3 4,270 33 9 690 89
8 48 2,890 3 22 99 21 3.6 99
9 59 1,450 3 24 98 18 3.0 99
10 32 17,560 3 616 97 30 8.2 99
Mean±SEM 37±4 11,426±3,666 3 737±421 91±61 9 ±4 109±68 98±1
Table 1. Plasma prolactin concentrations in patients with invasive giant prolactinoma before and during cabergoline treatmentAverage treatment duration was 19 months (range, 9-43 mon-
ths). Cabergoline was well tolerated by all patients. None of
the patients required dose reduction or discontinuation due
to side effects. 
After 3 months of cabergoline treatment, serum prolactin
concentrations were decreased dramatically (Table 1, Fig. 1).
In all patients except one (No. 7), serum prolactin concentra-
tion was reduced by 97% after 3 months of treatment. At the
last follow-up, average serum prolactin levels were decreased
by 98%, with 6 of the 10 patients having serum prolactin
concentrations <20 ng/mL. Patient No. 7, who experienced
only a 33% decrease at 3 months due to irregular medication,
showed an 89% decrease in serum prolactin concentration
after 9 months of treatment. These findings indicate that
cabergoline treatment was very effective in reducing serum
prolactin levels in all patients with invasive giant prolacti-
noma.
When we analyzed changes in tumor size during cabergo-
line treatment, we observed a significant reduction (mean,
85±4%; range, 57-98%) at first MRI follow-up, performed
after 3 to 12 months of treatment (Table 2, Fig. 2). Except for
Patient No. 7, all patients showed a significant decrease in
tumor size within 6 months of treatment (mean, 86±3%;
range, 70-90%). A further reduction in tumor size was obser-
ved with a longer duration of cabergoline treatment. Caber-
goline treatment for >12 months caused a greater reduction
in tumor size compared with the treatment for <12 months
(97±1% vs. 78±7%, P<0.05), indicating that long-term
cabergoline treatment was very efficient for reduction of tumor
size in giant prolactinoma.
During treatment, three patients showed improvements
in visual field defects. Serum testosterone concentrations re-
turned to the normal level in three of seven patients who had
initially hypogonadism (mean testosterone levels; 1.2 to 4.0
ng/mL). There was no further decrease in other pituitary hor-
mones during cabergoline treatment (data not shown).
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Case
No.
Basal tumor 
volume (μ L)
Treatment
duration
(months)
Treatment 
duration
(months)
Tumor 
volume
(μ L)
Decrease
(% of basal)
Tumor 
volume
(μ L)
Decrease
(% of basal)
Initial follow-up Last follow-up
17 0 ×46×55 11 16×15×13 97 23 12×10×89 9
24 6 ×25×35 5 22×21×14 84 17 12×9×14 96
34 0 ×26×24 5 28×9×16 84 -- -
45 0 ×34×33 3 23×13×21 89 -- -
54 6 ×28×35 4 34×16×25 70 -- -
66 7 ×46×56 6 30×20×30 90 16 17×15×25 96
74 8 ×32×30 4 32×25×25 57 -- -
84 1 ×32×26 7 21×15×16 85 17 13×11×11 95
94 0 ×25×31 12 17×16×23 95 -- -
10 63×35×39 7 17×14×16 98 30 10×9×99 9
Mean±SEM 6.4±18 5 ±4 20.6±39 7 ±1
Table 2. Changes in tumor size in patients with invasive giant prolactinoma before and during cabergoline treatment
Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8
Case 9
Case 10
Fig. 1. Serum prolactin concentrations
before and during cabergoline treatment
in 10 men with invasive giant prolactino-
ma.
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DISCUSSION
In the present study, the patients with invasive giant pro-
lactinoma were all males. Prolactinomas in males are known
to be more invasive and growing more rapidly (5), suggest-
ing that male prevalence of large prolactinoma may be due
to its aggressive nature, not merely due to delayed diagnosis
(6). The extreme aggressive type of macroprolactinoma is inva-
sive giant prolactinoma. 
A previous study reported that long-term cabergoline treat-
ment (mean duration, 15 months) in males and females with
macroprolactinoma resulted in a 61% prolactin normaliza-
tion rate and a 66% tumor shrinkage rate (7). Similarly, in
another study, the rate of prolactin normalization was approx-
imately 75% in males with macroprolactinoma following 24
months of cabergoline treatment (8). There were two previ-
ous studies showing the outcomes of cabergoline treatment
in giant prolactinoma (2, 9). In one study, cabergoline treat-
ment normalized prolactin concentrations in 5 of 10 men
with giant prolactinoma. Furthermore, in the remaining five
patients, serum prolactin levels were decreased by 94% of
the pretreatment levels after a mean 39 months of cabergo-
line therapy (9). In the other study, cabergoline treatment
for 1-50 months normalized prolactin levels in eight out of
ten patients with giant prolactinoma (2). 
Consistent with the previous reports, our study showed
that cabergoline induced a profound reduction (>95%) in
serum prolactin levels within 3 months in 7 among 10 pati-
ents. At last follow-up (average treatment duration, 19 mon-
ths), serum prolactin levels were decreased to 2% of basal lev-
els in all 10 patients and normalized in 5 patients. Tumor
shrinkage was significant (86% reduction) within 6 months
although a further decrease (97%) in tumor size was observed
after >12 months of cabergoline treatment. Compared to the
previous reports (2, 9), our data showed that lower dose (0.5-
1 mg/week) of cabergoline treatment induced more rapid
decreases in both serum prolactin levels and tumor volume.
The reason for the excellent outcome in our patients is unclear.
However, it may result from that our study included the pati-
ents with more aggressive prolactinoma as suggested by larg-
er tumor size and higher basal prolactin levels. 
When we reviewed the outcome of bromocriptine treat-
ment in giant prolactinoma, bromocriptine treatment for
more than 5 yr caused an overall 99.8% decrease in prolactin
levels and a mean 68% decrease in tumor volume (1). Alth-
ough outcomes of bromocriptine treatment are comparable
to those of cabergoline, some patients are intolerant to bro-
mocriptine due to side effects such as nausea, orthostatic dizzi-
ness, fatigue and nasal congestion (10). In our study, none of
the patients experienced any adverse effects during cabergo-
line treatment, and none experienced disturbances in the other
pituitary functions or cerebrospinal fluid rhinorrhea, a rare
complication of dopamine agonist treatment (11-13). Thus
cabergoline treatment is safe and well-tolerated.
Complete surgical removal of giant prolactinomas via the
transsphenoidal approach is very difficult because these tumors
invade local surrounding structures, including the cavernous
sinus and optic chiasm. Therefore, the persistence and recur-
rence of giant prolactinoma after surgery are very high (14,
15). Biochemical cure is also rare even after extensive tumor
removal. Indeed, during the same study period, nine patients
were diagnosed with invasive giant prolactinoma but under-
went transsphenoidal tumor resection before a referral to our
department. Although serum prolactin concentrations were
significantly decreased by surgery (from 2,655±474 to 381
±187 ng/mL), normalization of serum prolactin levels or
complete tumor resection was not achieved by surgery in all
patients (unpublished data), requiring additional medical
treatment.
Our study has limitations; it was a retrospective and non-
controlled study with small number of patients. However,
our data indicate that cabergoline treatment is a safe and effec-
tive treatment in male patients with invasive giant prolacti-
nomas. 
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